Redmile Group, LLC Adc Therapeutics Sa Transaction History

Redmile Group, LLC

$822 Million
Q2 2025

A detailed history of Redmile Group, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Redmile Group, LLC holds 15,666,731 shares of ADCT stock, worth $50.1 Million. This represents 5.11% of its overall portfolio holdings.

Number of Shares

15,666,731

Previous 15,666,731 -0.0%

Holding current value

$50.1 Million

Previous $22.1 Million 90.07%

% of portfolio

5.11%

Previous 2.32%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.89 - $3.48 $4,698 - $8,651	-2,486 Reduced 0.02%	15,666,731 $31.2 Million
Q3 2024 Nov 14, 2024	BUY	$2.59 - $4.01 $1.04 Million - $1.6 Million	400,000 Added 2.62%	15,669,217 $49.4 Million
Q1 2024 May 15, 2024	SELL	$1.66 - $5.29 $98,106 - $312,639	-59,100 Reduced 0.39%	15,269,217 $68.6 Million
Q4 2023 Feb 14, 2024	BUY	$0.47 - $1.79 $600,839 - $2.29 Million	1,278,382 Added 9.1%	15,328,317 $25.4 Million
Q2 2023 Aug 14, 2023	BUY	$1.9 - $2.66 $920,903 - $1.29 Million	484,686 Added 3.57%	14,049,935 $30.2 Million
Q1 2023 May 15, 2023	BUY	$1.92 - $5.45 $11.5 Million - $32.6 Million	5,974,400 Added 78.71%	13,565,249 $26.5 Million
Q4 2022 Feb 14, 2023	BUY	$2.87 - $5.24 $226,213 - $413,016	78,820 Added 1.05%	7,590,849 $29.1 Million
Q2 2022 Aug 15, 2022	BUY	$5.96 - $14.99 $474,416 - $1.19 Million	79,600 Added 1.07%	7,512,029 $59.7 Million
Q1 2022 May 16, 2022	SELL	$13.28 - $20.03 $247,008 - $372,558	-18,600 Reduced 0.25%	7,432,429 $109 Million
Q4 2021 Feb 14, 2022	SELL	$19.29 - $31.51 $1.51 Million - $2.47 Million	-78,300 Reduced 1.04%	7,451,029 $151 Million
Q3 2021 Nov 15, 2021	BUY	$20.45 - $30.0 $149,285 - $219,000	7,300 Added 0.1%	7,529,329 $204 Million
Q2 2021 Aug 16, 2021	BUY	$20.38 - $27.04 $4.35 Million - $5.78 Million	213,611 Added 2.92%	7,522,029 $183 Million
Q1 2021 May 17, 2021	BUY	$22.75 - $34.05 $12.5 Million - $18.7 Million	549,624 Added 8.13%	7,308,418 $178 Million
Q4 2020 Feb 16, 2021	BUY	$25.26 - $38.02 $10.2 Million - $15.4 Million	405,700 Added 6.39%	6,758,794 $216 Million
Q3 2020 Nov 16, 2020	BUY	$32.87 - $51.05 $27.2 Million - $42.2 Million	827,224 Added 14.97%	6,353,094 $210 Million
Q2 2020 Aug 14, 2020	BUY	$29.65 - $46.81 $164 Million - $259 Million	5,525,870 New	5,525,870 $259 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

67.9M

Call Options Held

68.2K

Put Options Held

75.8K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $248M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Adc Therapeutics Sa Transaction History